Marc joined Financiere Arbevel late 2014. He runs a ca. €40m private equity fund dedicated to life sciences.

Marc was a consultant (Bossard now Capgemini and Arthur D. Little) when he incepted BioProtein Technologies back in 1998. He ran such company for 8 years. He made Cellectis public on Paris stock market back in 2007 and was a CFO there for 7 years and in parallel CEO of Cellectis bioresearch. Most recently Marc was CEO at Cytoo, a biotech company based in the French Alps, which is now a leader in drug discovery for muscle-related diseases.